Recently, Skynor Medical officially announced the completion of nearly RMB100 million Series B funding, this round of financing was led by Zeyue Capital, Chuangban Investment and the old shareholder Anlong Fund with the investment, DAS Capital is the exclusive financial adviser.
This round of financing will be mainly used for new product development, clinical trials, marketing and company operation, etc. Assist to promote the certificates application and commercialization of more than 15 products. Also support the company to develop the neural and peripheral intervention market, and finally to create a global company with complete products portfolio.
Skynor medical was founded in 2014, is located in the Shanghai international medical valley. The company focus on the development of cutting-edge vascular minimally invasive intervention products with high entry barriers, covering two product lines of neurovascular intervention and peripheral intervention, dedicated to provide a complete treatment solution for patients with stroke, peripheral vascular disease .
As a fast-growing company, Skynor Medical has developed rapidly with excellent R&D efficiency. Up to now, the company has owned 28 patents, and many products are in the application stage.
Post time: Feb-08-2021